150 related articles for article (PubMed ID: 22731825)
1. Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy.
Kondo S; Ueno H; Hashimoto J; Morizane C; Koizumi F; Okusaka T; Tamura K
BMC Cancer; 2012 Jun; 12():268. PubMed ID: 22731825
[TBL] [Abstract][Full Text] [Related]
2. IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
Song Y; Ji B; Jiang CX; Chen ZM; Yao NH; Mukaida N; Huang H
Pathol Res Pract; 2019 Dec; 215(12):152650. PubMed ID: 31585811
[TBL] [Abstract][Full Text] [Related]
3. Pilot study to relate clinical outcome in pancreatic carcinoma and angiogenic plasma factors/circulating mature/progenitor endothelial cells: Preliminary results.
Vizio B; Novarino A; Giacobino A; Cristiano C; Prati A; Brondino G; Ciuffreda L; Bellone G
Cancer Sci; 2010 Nov; 101(11):2448-54. PubMed ID: 20950371
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of altered N-glycosylation of circulating glycoproteins in patients with unresectable pancreatic cancer treated with gemcitabine.
Miyahara K; Nouso K; Morimoto Y; Kinugasa H; Kato H; Yamamoto N; Tsutsumi K; Kuwaki K; Onishi H; Ikeda F; Nakamura S; Shiraha H; Takaki A; Nakahara T; Miura Y; Asada H; Amano M; Nishimura S; Yamamoto K
Pancreas; 2015 May; 44(4):551-6. PubMed ID: 25875794
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer.
Mitsunaga S; Ikeda M; Shimizu S; Ohno I; Furuse J; Inagaki M; Higashi S; Kato H; Terao K; Ochiai A
Br J Cancer; 2013 May; 108(10):2063-9. PubMed ID: 23591198
[TBL] [Abstract][Full Text] [Related]
6. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.
Richards NG; Rittenhouse DW; Freydin B; Cozzitorto JA; Grenda D; Rui H; Gonye G; Kennedy EP; Yeo CJ; Brody JR; Witkiewicz AK
Ann Surg; 2010 Sep; 252(3):499-505; discussion 505-6. PubMed ID: 20739850
[TBL] [Abstract][Full Text] [Related]
7. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial.
Hess V; Glimelius B; Grawe P; Dietrich D; Bodoky G; Ruhstaller T; Bajetta E; Saletti P; Figer A; Scheithauer W; Herrmann R
Lancet Oncol; 2008 Feb; 9(2):132-8. PubMed ID: 18249033
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase-I/II study using a combination of gemcitabine and docetaxel in metastasized and unresectable, locally advanced pancreatic carcinoma.
Ridwelski K; Fahlke J; Kuhn R; Hribaschek A; Kettner E; Greiner C; Florschuetz A; Manger T; Wilhelm G; Klein H; Hahnfeld S; Lippert H; Meyer F
Eur J Surg Oncol; 2006 Apr; 32(3):297-302. PubMed ID: 16414235
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine chemotherapy: clinical characteristics of long-term survivors].
An SG; Kim DU; Song GA; Jang AL
Korean J Gastroenterol; 2014 Dec; 64(6):356-63. PubMed ID: 25530587
[TBL] [Abstract][Full Text] [Related]
11. Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma.
Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Kondo N; Nakagawa N; Sueda T
J Surg Oncol; 2012 Aug; 106(2):174-80. PubMed ID: 22331838
[TBL] [Abstract][Full Text] [Related]
12. CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone.
Wasan HS; Springett GM; Chodkiewicz C; Wong R; Maurel J; Barone C; Rosbrook B; Ricart AD; Kim S; Spano JP
Br J Cancer; 2009 Oct; 101(7):1162-7. PubMed ID: 19724276
[TBL] [Abstract][Full Text] [Related]
13. Postoperative gemcitabine alone and concurrent with radiation therapy in locally advanced pancreatic carcinoma.
Ozkok S; Demirci S; Yalman D; Zeytunlu M; Nart D; Yuzer Y; Coker A; Goker E
Tumori; 2010; 96(4):560-7. PubMed ID: 20968135
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
Maréchal R; Demols A; Gay F; De Maertelaere V; Arvanitaki M; Hendlisz A; Van Laethem JL
Oncology; 2007; 73(1-2):41-51. PubMed ID: 18334830
[TBL] [Abstract][Full Text] [Related]
15. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
Toyama Y; Yoshida S; Saito R; Kitamura H; Okui N; Miyake R; Ito R; Son K; Usuba T; Nojiri T; Yanaga K
World J Surg Oncol; 2013 Jan; 11():3. PubMed ID: 23302293
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia inducible BHLHB2 is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma.
Wang W; Reiser-Erkan C; Michalski CW; Raggi MC; Quan L; Yupei Z; Friess H; Erkan M; Kleeff J
Biochem Biophys Res Commun; 2010 Oct; 401(3):422-8. PubMed ID: 20863812
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors.
Sezgin C; Karabulut B; Uslu R; Sanli UA; Goksel G; Yuzer Y; Goker E
Scand J Gastroenterol; 2005 Dec; 40(12):1486-92. PubMed ID: 16293561
[TBL] [Abstract][Full Text] [Related]
18. DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
Drouillard A; Puleo F; Bachet JB; Ouazzani S; Calomme A; Demetter P; Verset G; Van Laethem JL; Maréchal R
Br J Cancer; 2016 Nov; 115(10):1245-1252. PubMed ID: 27755532
[TBL] [Abstract][Full Text] [Related]
19. IL-18 paradox in pancreatic carcinoma: elevated serum levels of free IL-18 are correlated with poor survival.
Carbone A; Vizio B; Novarino A; Mauri FA; Geuna M; Robino C; Brondino G; Prati A; Giacobino A; Campra D; Chiarle R; Fronda GR; Ciuffreda L; Bellone G
J Immunother; 2009; 32(9):920-31. PubMed ID: 19816189
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]